Discover and read the best of Twitter Threads about #BariatricSurgery
Most recents (4)
@BassiMehak @MarcelYibirin @MondayNightIBD @kzhuangmd @agoldowskymd @IBD_FloMD @IBD_Afzali @babudayyeh @BolandBrigid @amjohnsonMD @PopovVioleta @RobertoSimonsMD @LauraChiuMD @PDulaiMD @HealthyLivingGI @oridamas @kehutchins77 @ven_satyam @MichelleKimMD @Chris_Velez_MD @traceyg_md @khalili_MD @ingrid_hickman @EdwardLoftus2 @ReemSharaiha @gutdoc18 @ThereziaR @CherylharrisRD @DBadurdeen @KellyHathornMD @GIdietitian 9/ Wt loss #Medications.
GLP-1:
✔️ ➕➕ for wt loss.
✔️ Safe in DM2 in IBD; may improve IBD activity
💥SE- nausea, 🤮, 💩🚽. Monitor closely
💥Orlistat- 🚫in IBD pts, esp with active small CD +/- chr malabsp syndrome
💥Phentermine-topiramate, Bupropion-naltrexone-⏬ efficacy
GLP-1:
✔️ ➕➕ for wt loss.
✔️ Safe in DM2 in IBD; may improve IBD activity
💥SE- nausea, 🤮, 💩🚽. Monitor closely
💥Orlistat- 🚫in IBD pts, esp with active small CD +/- chr malabsp syndrome
💥Phentermine-topiramate, Bupropion-naltrexone-⏬ efficacy
@BassiMehak @MarcelYibirin @MondayNightIBD @kzhuangmd @agoldowskymd @IBD_FloMD @IBD_Afzali @babudayyeh @BolandBrigid @amjohnsonMD @PopovVioleta @RobertoSimonsMD @LauraChiuMD @PDulaiMD @HealthyLivingGI @oridamas @kehutchins77 @ven_satyam @MichelleKimMD @Chris_Velez_MD @traceyg_md @khalili_MD @ingrid_hickman @EdwardLoftus2 @ReemSharaiha @gutdoc18 @ThereziaR @CherylharrisRD @DBadurdeen @KellyHathornMD @GIdietitian @GroverDheera @Empoweringpts9 @ownyourcrohns @RomyChamoun @JosephHabibi_MD @dunleavy_katie @ibdesis @yaransarkis @JPAchkarMD 10) Bariatric therapies in #IBD
🔦#Endoscopic balloon #IGB or sleeve #ESG
✔️Small series: safe & effective pubmed.ncbi.nlm.nih.gov/36474097/
@amjohnsonMD @babudayyeh
✂️Surgery
✔️Safe & effective
✔️Similar outcomes to non-IBD re:postop complications, Wt loss, postop deficiencies
🔦#Endoscopic balloon #IGB or sleeve #ESG
✔️Small series: safe & effective pubmed.ncbi.nlm.nih.gov/36474097/
@amjohnsonMD @babudayyeh
✂️Surgery
✔️Safe & effective
✔️Similar outcomes to non-IBD re:postop complications, Wt loss, postop deficiencies
@BassiMehak @MarcelYibirin @MondayNightIBD @kzhuangmd @agoldowskymd @IBD_FloMD @IBD_Afzali @babudayyeh @BolandBrigid @amjohnsonMD @PopovVioleta @RobertoSimonsMD @LauraChiuMD @PDulaiMD @HealthyLivingGI @oridamas @kehutchins77 @ven_satyam @MichelleKimMD @Chris_Velez_MD @traceyg_md @khalili_MD @ingrid_hickman @EdwardLoftus2 @ReemSharaiha @gutdoc18 @ThereziaR @CherylharrisRD @DBadurdeen @KellyHathornMD @GIdietitian @GroverDheera @Empoweringpts9 @ownyourcrohns @RomyChamoun @JosephHabibi_MD @dunleavy_katie @ibdesis @yaransarkis @JPAchkarMD @Spencerkelley7 @AsadurRahman87 @BabuPMohan2 @DushDahiya @BilalMohammadMD @GI_PharmD @joshsteinbergMD @john_damianosMD @doctornikkid 11) ⛳️Summary
🔺Up to 40% of #IBD pts have #Obesity
🔺Obesity ⬆️risk of neg outcomes in #IBD
🔺Obesity can affect overall 🔥burden,⬇️efficacy of biologics,⬆️risk of IBD-related ✂️
🔺Medical Rx & bariatric procedures for obesity are effective & safe in IBD
🗳️#CME #PostB2B polls👇
🔺Up to 40% of #IBD pts have #Obesity
🔺Obesity ⬆️risk of neg outcomes in #IBD
🔺Obesity can affect overall 🔥burden,⬇️efficacy of biologics,⬆️risk of IBD-related ✂️
🔺Medical Rx & bariatric procedures for obesity are effective & safe in IBD
🗳️#CME #PostB2B polls👇
The word ‘#obese’ is now considered unacceptable by the world’s academic community and should be changed by the @WHO to #obesity - because: a person has a disease called obesity and that person is NOT the disease itself. @pattynece @Eggface @PaulDavidsonPhD @ConscienHealth
About 5 years ago I had 150 new people following me every day. My tweets were seen by many then one day it all stopped…. A website in Europe detected that I was #shadowbanned by @twitter 1/
Clearly my tweets and retweets were not getting the same impact - I had gained notoriety from my social media presence and I had no answers. I had no recourse. No one at #twitter would respond to my texts, emails, or calls. So… I just worked harder… 2/
GLP-1-based therapies are slowly approaching #bariatricsurgery level #weightloss and more exciting science to come. There is the impressive SURMOUNT-1 trial for tirzepatide #obesity nejm.org/doi/full/10.10…
Among the compelling findings, 63% of subjects achieved > 20% #weightloss with 15 mg once weekly Tirzepatide over 72 weeks #obesity nejm.org/doi/full/10.10…
